Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Current Liabilities (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Total Current Liabilities for 7 consecutive years, with $38.5 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 92.96% to $38.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.5 million through Dec 2025, up 92.96% year-over-year, with the annual reading at $38.5 million for FY2025, 92.96% up from the prior year.
  • Total Current Liabilities hit $38.5 million in Q4 2025 for Eton Pharmaceuticals, down from $44.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $44.2 million in Q3 2025 to a low of $3.1 million in Q2 2021.
  • Historically, Total Current Liabilities has averaged $14.9 million across 5 years, with a median of $10.0 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: fell 13.04% in 2022 and later surged 151.52% in 2023.
  • Year by year, Total Current Liabilities stood at $4.6 million in 2021, then surged by 41.75% to $6.5 million in 2022, then soared by 151.37% to $16.2 million in 2023, then grew by 22.82% to $19.9 million in 2024, then soared by 92.96% to $38.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for ETON at $38.5 million in Q4 2025, $44.2 million in Q3 2025, and $38.6 million in Q2 2025.